Cord Blood America Announces CEO Matthew Schissler to Appear Live on MN1.com, Key Investor Internet Program in Rescheduled Interview.LOS ANGELES, Calif. -- Cord Blood America, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CBAI CBAI The Community Bankers Association of Illinois CBAI Contract Bridge Association of Ireland (UK) ), the umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that Matthew Schissler, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will appear live at 9:30 a.m. Pacific on Thursday, December 7, on the popular MN1.com market news show in a rescheduled interview to discuss the Company's achievements and future outlook. Investors can hear the interview at http://www.MN1.com. Market News First is the only online, live, IPTV (Internet Protocol TV) Also called "TV over IP," IPTV delivers scheduled TV programs and video-on-demand (VOD) via the IP protocol and digital streaming techniques used to watch video on the Internet. provider bringing market news and features to interested investors. Market News First is noted for its one-on-one interviews with the executives of public companies to deliver the answers to the questions that investors are currently asking. "It is important that we use venues such as this to tell our outstanding story and to interest new investors in Cord Blood America," said Mr. Schissler. Cord Blood America recently announced the purchase of the operating entity and assets of CorCell, Philadelphia, Pa., which collects umbilical cord blood stem cells from hospitals in all 50 states and internationally. Cord Blood America is now the fourth largest out of 26 family cord blood stem cell banks in the U.S. About Cord Blood America Cord Blood America (OTCBB:CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells cord blood stem cells Umbilical cord blood Hematology A therapeutic 'agent' containing concentrated hematopoietic stem cells for Pts with BM depleted–'wiped out' by disease; they are transfused into HLA-identical siblings and used to reconstitute the BM of offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. : CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com. Forward-Looking Statements Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments Medical researchers believe that stem cell treatments have the potential to change the face of human disease and alleviate suffering. A number of stem cell treatments already exist, although most are still experimental and/or costly, with the notable exception of bone marrow , and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion